ADTX
Aditxt, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -74.1%
- EBITDA
- —
- EBIT
- +16.5%
- EPS
- +100.0%
- Free cash flow
- +17.5%
- Operating cash flow
- +17.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -84.9%
- EBITDA
- -48.4%
- EBIT
- +29.8%
- Net income
- -21.1%
- EPS
- +62.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026